Eapen, 2017 - Google Patents
Relapsed acute lymphoblastic leukemia: Is it crucial to achieve molecular remission prior to transplant?Eapen, 2017
- Document ID
- 12751626452612618775
- Author
- Eapen M
- Publication year
- Publication venue
- Best Practice & Research Clinical Haematology
External Links
Snippet
In patients with acute lymphoblastic leukemia (ALL) the risk of recurrent leukemia influences the choice of treatment between chemotherapy and allogeneic hematopoietic cell transplantation. The evaluation of minimal residual disease (MRD) is now considered to be …
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma 0 title abstract description 41
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Luen et al. | Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy | |
Pui et al. | Outcome of children with hypodiploid acute lymphoblastic leukemia: a retrospective multinational study | |
Koti et al. | Sex differences in bladder cancer immunobiology and outcomes: a collaborative review with implications for treatment | |
Bane et al. | Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy | |
Grivas et al. | The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches | |
Barbano et al. | Aberrant Keap1 methylation in breast cancer and association with clinicopathological features | |
Pabinger et al. | Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients–results from the Vienna Cancer And Thrombosis Study (CATS) | |
Kipps et al. | Long-term studies assessing outcomes of ibrutinib therapy in patients with del (11q) chronic lymphocytic leukemia | |
Groeschel et al. | Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group | |
Cao et al. | Prognostic value of VEGF in hepatocellular carcinoma patients treated with sorafenib: a meta-analysis | |
Duan et al. | Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine | |
MX369628B (en) | Nano46 genes and methods to predict breast cancer outcome. | |
Chen et al. | Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome–positive acute lymphoblastic leukemia | |
Kim et al. | VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma | |
Versluis et al. | Graft-versus-leukemia effect of allogeneic stem-cell transplantation and minimal residual disease in patients with acute myeloid leukemia in first complete remission | |
Arif et al. | The role of Nanog expression in tamoxifen-resistant breast cancer cells | |
Te Raa et al. | TP53 dysfunction in CLL: Implications for prognosis and treatment | |
Khosravi-Maharlooei et al. | Expression pattern of alternative splicing variants of human telomerase reverse transcriptase (hTERT) in cancer cell lines was not associated with the origin of the cells | |
O'Cathail et al. | NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer | |
May et al. | EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer | |
Martei et al. | Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes | |
Nakamoto et al. | Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer | |
Lim et al. | Single-cell RNA sequencing in melanoma: what have we learned so far? | |
Wouters et al. | Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design | |
Ghesquières et al. | Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts |